{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:40:35Z","timestamp":1789609235638,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jim.2018.07.006","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T19:14:01Z","timestamp":1532027641000},"page":"15-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management"],"prefix":"10.1016","volume":"461","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7225-8228","authenticated-orcid":false,"given":"Meera","family":"Sridharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.V.","family":"Willrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2018.07.006_bb0005","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jim.2018.07.006_bb0010","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00467-017-3813-2","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update","volume":"33","author":"Ardissino","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.jim.2018.07.006_bb0015","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/clinids\/1.6.912","article-title":"Hemolytic activity of plasma and urine from rabbits experimentally infected with legionella pneumophila","volume":"1","author":"Baine","year":"1979","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.jim.2018.07.006_bb0020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/RHU.0000000000000425","article-title":"Renal thrombotic Microangiopathy in proliferative lupus nephritis: risk factors and clinical outcomes: a case-control study","volume":"22","author":"Barrera-Vargas","year":"2016","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.jim.2018.07.006_bb0025","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jim.2018.07.006_bb0030","series-title":"Disorders of Intracellular Cobalamin Metabolism","author":"Carrillo","year":"1993"},{"key":"10.1016\/j.jim.2018.07.006_bb0035","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ejim.2013.05.007","article-title":"Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies","volume":"24","author":"Cataland","year":"2013","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.jim.2018.07.006_bb0040","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jim.2018.07.006_bb0045","series-title":"General Best Practice Guidelines for Immunization: Altered Immunocompetence","author":"CDC","year":"2017"},{"key":"10.1016\/j.jim.2018.07.006_bb0050","series-title":"Meningococcal ACIP Recommendations","author":"CDC","year":"2017"},{"key":"10.1016\/j.jim.2018.07.006_bb0055","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jim.2018.07.006_bb0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2018.07.006_bb0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2016.99","article-title":"Anti-complement-factor H-associated glomerulopathies","volume":"12","author":"Durey","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.jim.2018.07.006_bb0070","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jim.2018.07.006_bb0075","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor Eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jim.2018.07.006_bb0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after Eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jim.2018.07.006_bb0085","series-title":"Alexion Briefing Information for the November 18, 2014, Meeting of the Drug Safety and Risk Management Advisory Committee","author":"FDA","year":"2014"},{"key":"10.1016\/j.jim.2018.07.006_bb0090","series-title":"US Department of Health and Human Services, Silver Springs","article-title":"Soliris product insert","author":"FDA","year":"2017"},{"key":"10.1016\/j.jim.2018.07.006_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acc.2016.06.001","article-title":"Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation","volume":"77","author":"Frazer-Abel","year":"2016","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/j.jim.2018.07.006_bb0100","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jim.2018.07.006_bb0105","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jim.2018.07.006_bb0110","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/bmt.2017.39","article-title":"Transplant-associated thrombotic microangiopathy: opening Pandora's box","volume":"52","author":"Gavriilaki","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jim.2018.07.006_bb0115","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1038\/ki.2008.622","article-title":"The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS registry, 1989\u20132007","volume":"112","author":"George","year":"2009","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.jim.2018.07.006_bb0120","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2018.07.006_bb0125","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.mayocp.2016.05.015","article-title":"Thrombotic microangiopathy care pathway: a consensus statement for the mayo clinic complement alternative pathway-thrombotic microangiopathy (cap-tma) disease-oriented group","volume":"91","author":"Go","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jim.2018.07.006_bb0130","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.2010.222","article-title":"Atypical hemolytic uremic syndrome: telling the difference between H and Y","volume":"78","author":"Goicoechea De Jorge","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.jim.2018.07.006_bb0140","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \"kidney disease: improving global outcomes\" (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.jim.2018.07.006_bb0145","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.jim.2018.07.006_bb0150","doi-asserted-by":"crossref","first-page":"550","DOI":"10.12659\/AOT.905917","article-title":"Eculizumab in renal transplantation: a 2017 update","volume":"22","author":"Grenda","year":"2017","journal-title":"Ann. Transplant."},{"key":"10.1016\/j.jim.2018.07.006_bb0155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fped.2014.00097","article-title":"Extra-renal manifestations of complement-mediated thrombotic microangiopathies","volume":"2","author":"Hofer","year":"2014","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.jim.2018.07.006_bb0160","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","article-title":"HUS and atypical HUS","volume":"129","author":"Jokiranta","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jim.2018.07.006_bb0165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.imlet.2014.01.014","article-title":"Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome","volume":"160","author":"Jozsi","year":"2014","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jim.2018.07.006_bb0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/ki.2011.330","article-title":"Interpretation of genetic variants of uncertain significance in atypical hemolytic uremic syndrome","volume":"81","author":"Kavanagh","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.jim.2018.07.006_bb0175","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1055\/s-0030-1262887","article-title":"Transplantation in atypical hemolytic uremic syndrome","volume":"36","author":"Kavanagh","year":"2010","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.jim.2018.07.006_bb0180","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.jim.2018.07.006_bb0185","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2018.07.006_bb0190","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jim.2018.07.006_bb0195","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.jim.2018.07.006_bb0200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.jim.2018.07.006_bb0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.jim.2018.07.006_bb0210","first-page":"310","article-title":"Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome","volume":"10","author":"Macia","year":"2017","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.jim.2018.07.006_bb0215","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.jim.2018.07.006_bb0220","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jim.2018.07.006_bb0225","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/asheducation.V2012.1.617.3798924","article-title":"Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?","volume":"2012","author":"Nester","year":"2012","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.jim.2018.07.006_bb0230","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2018.07.006_bb0235","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jim.2018.07.006_bb0240","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault De Latour","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jim.2018.07.006_bb0245","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2141.2012.09168.x","article-title":"The use of 'real-time' complement analysis to differentiate atypical haemolytic uraemic syndrome from other forms of thrombotic microangiopathies","volume":"158","author":"Prohaszka","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jim.2018.07.006_bb0250","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jim.2018.07.006_bb0255","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jim.2018.07.006_bb0260","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004330","article-title":"Can eculizumab be discontinued in aHUS?: case report and review of the literature","volume":"95","author":"Sahutoglu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jim.2018.07.006_bb0265","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jim.2018.07.006_bb0270","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jim.2018.07.006_bb0275","series-title":"Presented at the 44th Annual Meeting of the European Society for Pediatric Nephrology","article-title":"Eculizumab therapy for atypical hemolytic uremic syndrome in pediatric patients: efficacy and safety outcomes from retrospective study","author":"Simonetti","year":"2011"},{"key":"10.1016\/j.jim.2018.07.006_bb0280","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.transci.2016.04.012","article-title":"The alternative pathway of complement and the thrombotic microangiopathies","volume":"54","author":"Teoh","year":"2016","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.jim.2018.07.006_bb0285","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jim.2018.07.006_bb0290","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1097\/MPH.0000000000000505","article-title":"Disease recurrence after early discontinuation of Eculizumab in a patient with atypical hemolytic uremic syndrome with complement C3 I1157T mutation","volume":"38","author":"Toyoda","year":"2016","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.jim.2018.07.006_bb0295","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clim.2015.05.018","article-title":"Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome","volume":"160","author":"Volokhina","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jim.2018.07.006_bb0300","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.jim.2018.07.006_bb0305","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00467-016-3496-0","article-title":"Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome","volume":"32","author":"Westra","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.jim.2018.07.006_bb0310","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V126.23.1050.1050","article-title":"Novel genetic variants in complement-mediated thrombotic Microangiopath","volume":"126","author":"Yui","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jim.2018.07.006_bb0315","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat. Rev. Nephrol."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175917304520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175917304520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:34:17Z","timestamp":1758299657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175917304520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":62,"alternative-id":["S0022175917304520"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2018.07.006","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2018.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}